Lannett Company, Inc. (NYSE:LCI) has earned a consensus recommendation of “Hold” from the nine analysts that are covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $13.56.
Several analysts have issued reports on the company. SunTrust Banks assumed coverage on Lannett in a research report on Tuesday, March 19th. They issued a “hold” rating and a $9.00 target price on the stock. Zacks Investment Research raised Lannett from a “hold” rating to a “strong-buy” rating and set a $9.75 target price on the stock in a research report on Saturday, February 9th. Raymond James reaffirmed a “hold” rating on shares of Lannett in a research report on Thursday, December 13th. Finally, ValuEngine raised Lannett from a “sell” rating to a “hold” rating in a research report on Friday, March 22nd.
NYSE:LCI traded up $0.25 on Wednesday, hitting $8.39. The company’s stock had a trading volume of 758,242 shares, compared to its average volume of 1,523,076. The company has a quick ratio of 1.88, a current ratio of 2.44 and a debt-to-equity ratio of 2.29. The firm has a market capitalization of $319.80 million, a price-to-earnings ratio of 2.71 and a beta of 2.45. Lannett has a one year low of $3.33 and a one year high of $17.58.
Lannett (NYSE:LCI) last released its quarterly earnings data on Wednesday, February 6th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.18. The firm had revenue of $193.70 million for the quarter, compared to analyst estimates of $162.51 million. Lannett had a positive return on equity of 22.88% and a negative net margin of 39.44%. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.06 earnings per share. Equities research analysts expect that Lannett will post 2.14 EPS for the current year.
In related news, CEO Timothy C. Crew purchased 4,000 shares of Lannett stock in a transaction that occurred on Monday, February 11th. The shares were acquired at an average price of $8.48 per share, with a total value of $33,920.00. Following the completion of the transaction, the chief executive officer now directly owns 45,988 shares of the company’s stock, valued at approximately $389,978.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Patrick G. Lepore purchased 25,000 shares of Lannett stock in a transaction that occurred on Tuesday, February 12th. The shares were bought at an average cost of $8.93 per share, for a total transaction of $223,250.00. The disclosure for this purchase can be found here. 12.57% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the stock. State of Alaska Department of Revenue grew its position in Lannett by 15.2% during the fourth quarter. State of Alaska Department of Revenue now owns 11,478 shares of the company’s stock worth $56,000 after buying an additional 1,515 shares in the last quarter. Advisor Partners LLC acquired a new stake in Lannett during the fourth quarter worth approximately $60,000. Financial Gravity Companies Inc. acquired a new stake in Lannett during the fourth quarter worth approximately $60,000. Oregon Public Employees Retirement Fund acquired a new stake in Lannett during the fourth quarter worth approximately $64,000. Finally, Brave Asset Management Inc. acquired a new stake in Lannett during the fourth quarter worth approximately $65,000. 82.05% of the stock is currently owned by institutional investors and hedge funds.
Lannett Company Profile
Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.
Read More: How to Use a Moving Average for Trading
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.